Caris Life Sciences, Inc.
CAI- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- SEC CIK
- 0002019410
In the last 90 days, Caris Life Sciences, Inc. insiders filed 0 open-market purchases and 3 sales; 248 institutions reported holding it in 13F filings for Q2 2026, worth $2.75B in total; superinvestors Coatue Management and Duquesne Family Office hold it.
Key figures
- Market capClose on Nov 11, 2026
- $7.02B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $27.2M in total
- 3
- 13F holdersQ2 2026, +45 vs. previous quarter
- 248
- 13F valueReported value at the end of Q2 2026
- $2.75B
- Superinvestors holdingAt the end of Q2 2026
- 2
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $812.0M
- No comparable prior period
- Net income, FY2025
- -$68.1M
- No comparable prior period
- Free cash flow, FY2025
- $66.9M
- No comparable prior period
- Revenue, Q3 FY2026
- $275.4M
- +27.0% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $68.1M (8.4% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 11.5M
- Shares sold short
- Change
- −2.09M
- −15.4% vs. previous
- Days to cover
- 3.98
- At average daily volume
Superinvestors holding CAI, Q2 2026
Go to the superinvestors tab2 superinvestors report holding Caris Life Sciences, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Coatue Management
Philippe Laffont
0.4%
Caris Life Sciences, Inc.'s share of the portfolio
- Shares
- 9,819,992
- Value
- $175.0M
Duquesne Family Office
Stanley Druckenmiller
0.8%
Caris Life Sciences, Inc.'s share of the portfolio
- Shares
- 1,894,450
- Value
- $33.8M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Caris Life Sciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 23, 2026 (view filing)5:06 PM ET | Sep 22 | 1 day | Denton John RusselSee Remarks | SSale | −7.50K | $31.82 | −$238.6K | −4.1%174.9K after | |
| Sep 17, 2026 (view filing)6:08 PM ET | Sep 17 | Same day | Brille Brian JSee Remarks | SSale | −400.0K | $30.33 | −$12.1M | −63.5%230.3K after | |
| Sep 4, 2026 (view filing)4:59 PM ET | Sep 3-4 | 1 day | Spetzler David BaxleyPresident | SSale | −597.2K | $24.84 | −$14.8M | −33.5%1.18M after | 3 lots |
| Jul 13, 2026 (view filing)7:06 AM ET | May 15 | 59 daysLate | Halbert JonDirector | PPurchase | +68.0K | $14.56 | +$990.1K | +10.7%704.6K after | |
| May 12, 2026 (view filing) | May 11 | 1 day | Vacirca Jeff LDirector | PPurchase | +31.1K | $16.15 | +$501.5K | +166.7%49.7K after | |
| Dec 12, 2025 (view filing) | Dec 11 | 1 day | Power Luke ThomasSee Remarks | SSale | −62.3K | $26.57 | −$1.65M | −38.5%99.6K after | 2 lots10b5-1 |
| Nov 10, 2025 (view filing) | Nov 7 | 3 days | Spetzler David BaxleyPresident | PPurchase | +400 | $23.85 | +$9.54K | +0.1%460.8K after | |
| Nov 10, 2025 (view filing) | Nov 7 | 3 days | Denton John RusselSee Remarks | PPurchase | +4.18K | $24.09 | +$100.8K | +83.7%9.18K after | |
| Jun 23, 2025 (view filing) | Jun 20 | 3 days | Denton John RusselSee Remarks | PPurchase | +7.50K | $21.00 | +$157.5K | +6.5%123.6K after | |
| Jun 23, 2025 (view filing) | Jun 20 | 3 days | Brille Brian JSee Remarks | PPurchase | +30.0K | $21.00 | +$630.0K | +22.7%162.4K after |
Top 10 13F holders, Q2 2026
See all 248 holdersThe largest institutional positions in Caris Life Sciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 30,923,878 | $551.1M | 0.02% | +138,293+0.4% | Added |
| J. H. Whitney Equity Partners VI, LLC | 11,256,615 | $200.6M | 100.00% | −7,000,000−38.3% | Reduced |
| Coatue Management LLCSuperinvestorCoatue Management | 9,819,992 | $175.0M | 0.36% | 00.0% | Unchanged |
| Braidwell LP | 8,256,032 | $147.1M | 5.44% | +246,585+3.1% | Added |
| Sixth Street Partners Management Company, L.P. | 7,327,041 | $130.6M | 22.54% | −7,058,358−49.1% | Reduced |
| PointState Capital LP | 6,828,835 | $121.7M | 2.14% | −531,611−7.2% | Reduced |
| JPMorgan Chase & Co | 6,558,514 | $120.2M | 0.01% | +3,098,299+89.5% | Added |
| BlackRock, Inc. | 5,536,798 | $98.7M | 0.00% | +679,686+14.0% | Added |
| T. Rowe Price Investment Management, Inc. | 5,079,141 | $90.5M | 0.06% | −509,116−9.1% | Reduced |
| Vanguard Portfolio Management LLC | 4,844,431 | $86.3M | 0.00% | +1,085,969+28.9% | Added |
Holders of 5% or more of CAI
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Caris Life Sciences, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Halbert David D | 13G | 44.10%124.9M shares | New | Aug 13, 20251 filing | Aug 13, 2025 | SEC |
| FMR LLC | 13G/A | 13.40%37.8M shares | +2.60 ppfrom 10.80% | Feb 5, 20263 filings | Nov 5, 2026 | SEC |
| TSSP Sub-Fund HoldCo LLC | 13G | 8.80%24.4M shares | New | Jul 28, 20251 filing | Jul 28, 2025 | SEC |